Loading...
XNAS
BCRX
Market cap1.60bUSD
Dec 05, Last price  
7.59USD
1D
-3.07%
1Q
-8.22%
Jan 2017
19.91%
Name

BioCryst Pharmaceuticals Inc

Chart & Performance

D1W1MN
XNAS:BCRX chart
P/E
—
P/S
3.55
EPS
—
Div Yield, %
—
Shrs. gr., 5y
12.32%
Rev. gr., 5y
55.97%
Revenues
451m
+36.00%
151,8676,211,93671,237,90156,561,36974,589,00063,501,00019,643,00026,293,00017,331,00013,608,00048,257,00026,353,00025,186,00020,653,00048,835,00017,812,000157,170,000270,827,000331,412,000450,712,000
Net income
-89m
L-60.77%
-26,098,768-43,617,853-29,055,524-24,731,570-13,452,000-32,733,000-56,948,000-39,081,000-30,108,000-45,189,000-43,019,000-55,144,000-65,782,000-101,252,000-120,065,000-196,567,000-184,062,000-247,117,000-226,539,000-88,881,000
CFO
-52m
L-45.32%
-23,346,157-15,211,315-24,997,799-20,873,820-16,218,470-28,554,221-32,251,000-37,397,000-26,530,000-38,551,000-13,116,000-53,438,000-41,143,000-92,565,000-89,584,000-137,216,000-142,157,000-161,850,000-95,141,000-52,020,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
URL
https://www.biocryst.com/
IPO date
Mar 04, 1994
Employees
531
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT